5.13
Pepgen Inc (PEPG) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against PepGen Inc. (PEPG) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Is PepGen Inc. trending in predictive chart modelsTrade Performance Summary & Safe Swing Trade Setups - newser.com
Why PepGen Inc. stock remains resilientEarnings Overview Report & Long Hold Capital Preservation Plans - newser.com
Is PepGen Inc. stock poised for growthWeekly Risk Summary & Daily Price Action Insights - newser.com
Is PepGen Inc. reversing from oversold territoryWeekly Investment Report & AI Optimized Trade Strategies - newser.com
PepGen says FREEDOM clinical study achieves all key objectives - MSN
What data driven models say about PepGen Inc.’s futureWeekly Gains Report & Daily Profit Focused Screening - newser.com
Can trapped investors hope for a rebound in PepGen Inc.Earnings Beat & Safe Swing Trade Setups - newser.com
Using Bollinger Bands to evaluate PepGen Inc.2025 AllTime Highs & Accurate Entry/Exit Alerts - newser.com
Can momentum traders help lift PepGen Inc.Market Growth Summary & Verified Entry Point Detection - newser.com
Is PepGen Inc. stock gaining market shareJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle So - PharmiWeb.com
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society - Business Wire
Major Stakeholder Makes Bold Move with PepGen Inc. Stock Purchase! - TipRanks
PepGen Highlights Progress in Therapy for DM1 - TipRanks
PepGen Inc. Stock (PEPG) Opinions on Recent Insider Buying and Offering Closure - Quiver Quantitative
PepGen Inc. (PEPG) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Massive Investment Alert: PepGen Inc. Stock Sees Major Buy-In! - TipRanks
Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report - BioCentury
PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data - Insider Monkey
PepGen (PEPG) Price Target Increased by 21.95% to 8.50 - Nasdaq
Wedbush Cuts Price Target on PepGen to $8 From $9, Keeps Outperform Rating - MarketScreener
What analysts say about PepGen Inc stockInstitutional Buying Trends & Follow Top Performers in the Community - earlytimes.in
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters Option to Purchase Additional Shares - MarketScreener
Top Biotech Stocks To Watch TodaySeptember 25th - MarketBeat
What is Wedbush’s Estimate for PepGen FY2028 Earnings? - Defense World
PepGen Stock Plummets on Secondary Offering News - timothysykes.com
A Look at PepGen (PEPG) Valuation After Positive Clinical Data and $100M Equity Raise - Yahoo Finance
PepGen Inc. Announces Public Offering Agreement - The Globe and Mail
PepGen raises $115 million in public offering to fund clinical trials - Investing.com Nigeria
PEPG News Today | Why did PepGen stock drop today? - MarketBeat
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - BioCentury
大文字化:
|
ボリューム (24 時間):